Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +17.95%
#2 clBTC clBTC +12.17%
#3 OpenEden OpenEden +11.49%
#4 Wrapped Ether (Mantle Bridge) Wrapped Ether (Mantle Bridge) +8.67%
#5 Mantle Staked Ether Mantle Staked Ether +8.27%
#6 Palladium Network Palladium Network +7.82%
#7 Not in Employment, Education, or Training Not in Employment, Education, or Training +6.66%
#8 Prom Prom +6.59%
#9 Zest Protocol Zest Protocol +6.19%
#10 EfficientFrontier EfficientFrontier +4.43%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Brickell Biotech, Inc. Brickell Biotech, Inc.

Brickell Biotech, Inc.

BBI
Classificação em ações #40377
Brickell Biotech, Inc. is a pharmaceutical company currently in the clinical... Brickell Biotech, Inc. is a pharmaceutical company currently in the clinical development phase, dedicated to creating prescription medicines for various debilitating conditions, including autoimmune and inflammatory disorders, primarily within the United States. Its product pipeline includes sofpironium bromide, which has successfully finished Phase III clinical trials for treating excessive underarm sweating (primary axillary hyperhidrosis). Other notable candidates are BBI-02, an oral DYRK1A inhibitor targeting autoimmune and inflammatory diseases, and BBI-10, a covalent stimulator of interferon genes (STING) inhibitor, being explored for autoinflammatory and rare genetic illnesses. The company is also advancing next-generation kinase inhibitors. Brickell Biotech collaborates with several partners, such as Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. Established in 2009, its main office is located in Boulder, Colorado.
Preço da ação
$2.35
Última sincronização: 2022-09-07
Valor de mercado
$162.94K
Variação (1 dia)
2.17%
Variação (1 ano)
0.00%
País
US
Negociar Brickell Biotech, Inc. (BBI)

Categoria

Healthcare
Lucros da Brickell Biotech, Inc. (BBI)
Lucros em 2026 TTM: 0
De acordo com os últimos relatórios financeiros da Brickell Biotech, Inc., os ganhos atuais da empresa são de 0. Em 2026, a empresa teve ganhos de 0, igual a aos ganhos de 2026, que foram de 0. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Brickell Biotech, Inc. de 2026 a 2026
Lucros no final de cada ano
Ano Lucros Alterar
Não há dados suficientes para as datas fornecidas.
Lucros de empresas semelhantes ou concorrentes
Empresa Lucros Diferença de Lucros País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE